
Opinion|Videos|September 26, 2024
ESMO 2024: DESTINY-Breast12 Updates
Panelists discuss how ESMO 2024 presented important updates on primary end points and progression-free survival data from recent clinical studies.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5



































